Mar. 2 at 9:50 PM
$BLTE
Net Loss:
$25.32 million, compared to
$10.1 million for the same period in 2024.
Net Loss Per Share (Non-GAAP): -
$0.38, which beat analyst estimates of a -
$0.5572 loss.
Revenue:
$0, typical for a clinical-stage biotechnology company.
Full-Year 2025 Results
Net Loss:
$77.61 million, compared to
$36.14 million in 2024.
Loss per Share: -
$2.31, up from -
$1.18 in 2024.
R&D Expenses: Increased to
$45.4 million from
$29.9 million in 2024, reflecting advancing trials.
Cash Position: Strong, with
$352.9 million in cash and cash equivalents and
$419.7 million in treasury securities as of Dec 31, 2025.
